ALISO VIEJO, Calif.--(BUSINESS WIRE)--ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient ...
Please provide your email address to receive an email when new articles are posted on . In a trial, more than 75% of patients achieved a 20% reduction in IOP. The average IOP reduction was 7.4 mm Hg.
India Currents on MSN
Understanding early stage glaucoma
Manvinder’s story Manvinder*, a 62-year-old college professor from Minnesota, went for a routine eye examination. His ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results